Engineering other cells of the immune system

Chimeric antigen receptor engineering is now possible for immune cells other than T cells, including macrophages and invariant natural killer T cells.

Chimeric antigen receptor (CAR) T cell therapy is a therapeutic option for a variety of blood cancers but is ineffective at treating solid tumors and could cause inflammation and neurotoxicity. To overcome these barriers, scientists attach CARs to other immune cells. Unlike CAR T cells, CAR macrophages efficiently penetrate solid tumors, while CAR invariant natural killer T (iNKT) cells reduce the risk of hyperinflammation. In this webinar, Julie O’Neal will talk about using CAR iNKT cells as an alternative approach to treating multiple myeloma.

Topics to be covered

  • CAR iNKT cells as an alternative to CAR T cells for multiple myeloma treatment
  • Engineering CAR macrophages in situ for glioblastoma cell therapy 

Monday, December 18th, 2023 | 2:00 PM - 3:00 PM Eastern Time
This webinar will be available to view live and on demand.


Julie O’Neal, PhD

Julie O’Neal, PhD

Assistant Professor
Washington University in St. Louis

Supported by